Abstract
Pancreatic ductal adenocarcinoma is a malignant cancer resulting in mortality and has the lowest overall survival rate among cancer patients. It is unresponsive to chemo- and radio-therapy. Various strategies to increase the efficacy of treatment include drug delivery technologies such as polymeric micelles, liposomes, and nanoparticulate systems. Although passive targeting is attractive in highly vascularized and rapidly growing tumors, poorly vascularized and metastatic tumors remain a major challenge. Therefore, targeting specific markers using a molecular approach to deliver therapeutic agents including miRNA, siRNA, and conventional agents represents a promising strategy in the treatment of this aggressive disease. Using highly efficient, nontoxic, controlled released delivery systems such as polymeric nanoparticles, polymeric micelles, and liposomes to carry anticancer agents to cancer cells through particular is a compelling approach in pancreatic cancer therapy and diagnosis. This chapter discusses the current progress of targeted drug delivery approaches in pharmaceutical technology for pancreatic cancer treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
